RPS6KA5 and endothelial dysfunction: Targeting the MSK1/2 pathway with agents that activate MSK1 and MSK 2 might provide a useful therapeutic option for combating inflammation-induced endothelial dysfunction, measured by attenuated vasodilatation in the current studies.